FDA's proposed rule for pregnancy and lactation labeling: improving maternal child health through well-informed medicine use.
about
A Modified Murine Embryonic Stem Cell Test for Evaluating the Teratogenic Effects of Drugs on Early EmbryogenesisGPs' decision-making when prescribing medicines for breastfeeding women: Content analysis of a surveyFDA pregnancy risk categories and the CPS: do they help or are they a hindrance?Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancyPrescription drug use during pregnancy in developed countries: a systematic review.Use of medicines with unknown fetal risk among parturient women from the 2004 Pelotas Birth Cohort (Brazil).Medication management during pregnancy: role of the pharmacist.Balancing act: safe and evidence-based prescribing for women of reproductive age.Recent changes in pregnancy and lactation labeling: retirement of risk categories.Prescriptions for category D and X drugs during pregnancy in Taiwan: a population-based study.Performing elective surgery on the breastfeeding patient: a review of the literature.The 2015 US Food and Drug Administration Pregnancy and Lactation Labeling Rule.Emerging biologics in inflammatory bowel disease.Obstetrician-gynaecologist knowledge of and access to information about the risks of medication use during pregnancy.Defining a medication class as a teratogen: may the evidence be with you and not the FDA Pregnancy Risk Categories.A survey of drug information references emergency medicine clinicians utilize for prescribing in pregnant patients.
P2860
Q28551650-19C64C18-3B8E-4EE0-80BB-919CE4BFD8BBQ33544920-790460D1-055B-4262-8874-EA32CBEFBDC2Q33724195-4A5B7AE8-B7B7-4FBA-8F7F-85E68F18CBC2Q35596724-CB184865-C54A-4ED0-969D-C8E2CF774F66Q36176863-86FDC873-F4CF-419E-B760-006DB9B1BC99Q36546439-C9D0574B-DEFA-44D9-B2C8-1977DD4CDFA6Q37931741-712296C0-A827-4F44-A6BF-F1A3BA9B1983Q38023508-1F79A979-57F4-4727-9885-BA56B5410545Q38175895-F3147C7A-ADD1-4E42-AFFD-C59CBB9E8AFFQ38191890-BE1F52F5-3BA4-47F7-BEB5-32B6F36071D0Q38207518-A549D83C-A62F-4C4D-8614-5D773E3648DDQ38757265-FE281A38-755C-4A10-BEB1-8430F9FEAFACQ39004625-7125C832-8FE9-4C23-A0FF-3DF9DD5EF6C8Q43135374-61E018C0-ABF6-4BD8-9691-5C781D30449FQ44252822-5FFF58A3-F3FA-473E-A000-D204ED62E502Q50146552-0F1E6403-1AD4-4BC0-A751-CA728848EECC
P2860
FDA's proposed rule for pregnancy and lactation labeling: improving maternal child health through well-informed medicine use.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
FDA's proposed rule for pregna ...... gh well-informed medicine use.
@ast
FDA's proposed rule for pregna ...... gh well-informed medicine use.
@en
type
label
FDA's proposed rule for pregna ...... gh well-informed medicine use.
@ast
FDA's proposed rule for pregna ...... gh well-informed medicine use.
@en
prefLabel
FDA's proposed rule for pregna ...... gh well-informed medicine use.
@ast
FDA's proposed rule for pregna ...... gh well-informed medicine use.
@en
P356
P1476
FDA's proposed rule for pregna ...... gh well-informed medicine use.
@en
P2093
Karen B Feibus
P2888
P304
P356
10.1007/BF03161214
P577
2008-12-01T00:00:00Z